Lifecore Biomedical, Inc. (LFCR)
NASDAQ: LFCR · Real-Time Price · USD
7.63
-0.14 (-1.80%)
Dec 5, 2025, 4:00 PM EST - Market closed

Company Description

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States.

The company engages in the manufacturing of hyaluronate acid (HA) in bulk form, as well as formulated and filled syringes, cartridges, and vials for injectable products used in treating a range of medical conditions and procedures.

Its product development services include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and production of materials for clinical studies.

The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022.

Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Lifecore Biomedical, Inc.
Lifecore Biomedical logo
Country United States
Founded 1986
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 406
CEO Paul Josephs

Contact Details

Address:
3515 Lyman Boulevard
Chaska, Minnesota 55318
United States
Phone 952 368 4300
Website lifecore.com

Stock Details

Ticker Symbol LFCR
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year June - May
Reporting Currency USD
CIK Code 0001005286
ISIN Number US5147661046
Employer ID 94-3025618
SIC Code 2834

Key Executives

Name Position
Paul Josephs President, Chief Executive Officer and Director
Ryan D. Lake CPA Executive Vice President and Chief Financial Officer
Thomas D. Salus Chief Legal and Administration Officer and Corporate Secretary
Thomas Guldager Senior Vice President of Operations
Aaron Perlitsh Director of Internal Audit and Chief Compliance Officer
Jackie Q. Klecker Executive Vice President of Quality and Development Services
Mark DaFonseca Chief Commercial Officer
Parker K. Javid Vice President

Latest SEC Filings

Date Type Title
Nov 17, 2025 8-K Current Report
Nov 6, 2025 10-Q Quarterly Report
Nov 6, 2025 8-K Current Report
Oct 31, 2025 8-K Current Report
Oct 17, 2025 SCHEDULE 13G/A Filing
Sep 30, 2025 EFFECT Notice of Effectiveness
Sep 30, 2025 424B3 Prospectus
Sep 26, 2025 8-K Current Report
Sep 23, 2025 S-3 Registration statement under Securities Act of 1933
Sep 18, 2025 DEF 14A Other definitive proxy statements